Provention Bio, Inc. is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay or prevention of clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Show more

Location: 55 Broad Street, 2Nd Floor, New Jersey, 07701, US | Website: www.proventionbio.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing


Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$24.98

Open

$24.98

Volume

218,200

Day Range

$24.98 - $24.98

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

4.62%

Institutional Own.

53.26%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date